Latest news with #RVTY
Yahoo
06-08-2025
- Business
- Yahoo
Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research WALTHAM, Mass., August 06, 2025--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows and intended for researchers studying G protein-coupled receptors (GPCRs) or antibody-drug conjugates (ADCs). They offer a scalable, accurate, and easy-to-implement solution for monitoring antibody, ADC, or receptor internalization. Developed for use with standard plate readers, pHSense reagents combine a pH-sensitive dye and a time-resolved fluorescence (TRF) readout to allow for the delivery of robust kinetics of internalization and high signal-to-background—even at low endogenous receptor expression levels. Fully compatible with Revvity's multimode detection platforms, pHSense reagents have the potential to significantly enhance detection capability while simplifying integration into existing drug discovery workflows. By enabling more efficient screening and characterization of promising therapeutic candidates, pHSense reagents can help researchers accelerate preclinical development timelines, potentially reducing overall development costs and contributing to more efficient advancement of candidates toward clinical evaluation. "pHSense reagents fill a critical gap in internalization assay technologies, directed towards enabling researchers to gain faster, more reliable insights using more physiologically relevant conditions," said Craig Monell, senior vice president, reagents at Revvity. "With this launch, Revvity reinforces its commitment to advancing drug discovery through innovative tools that are focused on improving data quality, throughput, and reproducibility." With a growing focus on receptor trafficking in drug development and increasing demand for accurate, high-throughput tools, pHSense reagents offer support for emerging trends in oncology and precision medicine, particularly in ADC development. The innovative design focused on addressing major limitations of current offerings such as low throughput and suboptimal signal-to-noise ratios. For details on Revvity's wide-ranging portfolio of reagents – including immunoassays, gene editing and modulation tools, primary and secondary antibodies, and molecular biology solutions – visit About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries. Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram. View source version on Contacts Investor Relations: Steve Media Relations: Chet Murray(781)
Yahoo
29-07-2025
- Business
- Yahoo
Revvity Inc (RVTY) Q2 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ...
Revenue: $720 million in Q2, 3% organic growth. Adjusted EPS: $1.18, above expectations. Life Sciences Segment Growth: 4% organic growth. Diagnostics Segment Growth: 2% organic growth. Signals Software Growth: Over 30% organic growth. Free Cash Flow: $115 million in Q2, 83% conversion of adjusted net income. Operating Margin: 26.6% adjusted operating margin, down 210 basis points year over year. Share Repurchase: $293 million worth of shares repurchased in Q2. Full-Year Organic Growth Outlook: 2% to 4% range. Full-Year Adjusted EPS Outlook: $4.85 to $4.95. Net-Debt-to-Adjusted-EBITDA Ratio: 2.6 times. Adjusted Tax Rate: 19.1% in Q2. Warning! GuruFocus has detected 5 Warning Signs with RVTY. Release Date: July 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revvity Inc (NYSE:RVTY) achieved 3% organic growth in Q2 2025, in line with expectations, driven by strong performance in the Life Sciences segment. The Signals Software franchise experienced approximately 30% growth, setting a new record for orders in a single quarter. Revvity Inc (NYSE:RVTY) reported adjusted EPS of $1.18, which was above expectations and guidance. The company generated $115 million in free cash flow during the quarter, maintaining a solid 90% conversion rate year-to-date. Revvity Inc (NYSE:RVTY) repurchased nearly $300 million worth of stock in Q2, bringing total repurchases to nearly $450 million for the first half of the year. Negative Points The Diagnostics segment faced challenges in China due to changes in hospital lab reimbursement policies, impacting the Immunodiagnostics business. Revvity Inc (NYSE:RVTY) lowered its full-year organic growth outlook to 2% to 4%, down 1% from prior expectations. The company anticipates a meaningful pullback in its Immunodiagnostics business in China for the remainder of the year. Operating margins were pressured by lower volumes of high-margin diagnostic tests and recent changes in FX rates. The academic and government customer segment continued to show weakness, with revenue declining in the low single digits year over year. Q & A Highlights Q: Can you explain the guidance change related to organic growth, particularly in China, and whether other factors like VBP are involved? A: (Prahlad Singh, CEO) The majority of the impact is from the DRG policy in China, which affects multiplex tests. This policy reduces test volumes, but in the long term, it may lead to more single-plex tests, which are more expensive. We are working with stakeholders to potentially reverse these changes due to their impact on patient care. Q: Regarding margin changes, what are your expectations for 2026 margins, and what growth assumptions are they based on? A: (Maxwell Krakowiak, CFO) We expect a baseline operating margin of 28% for 2026, with margin expansion depending on organic growth levels. Typically, with high single-digit growth, we expect a 75 basis point margin expansion, and with mid-single-digit growth, about 50 basis points. Q: What are the revenue pacing assumptions for this year, and how do you see the impact of NIH funding and year-end budget flush? A: (Maxwell Krakowiak, CFO) We expect normal seasonality with a high single-digit ramp in both Life Sciences and Diagnostics. The fourth quarter will see a ramp-up in gel and larger volume in Signals Software. We assume academic and government funding will remain weak for the rest of the year. Q: Can you provide insights into the Life Sciences segment's performance, particularly reagents and instruments, and any guidance changes? A: (Prahlad Singh, CEO) Pharma-biotech showed stability with mid-single-digit growth, and our Life Sciences reagents business has grown for five consecutive quarters. While capital equipment spending is impacted, we remain optimistic about the reagents business. Q: How is the Software segment performing, and what are the expectations for growth in the second half? A: (Prahlad Singh, CEO) The Signals Software business had a record quarter with 32% organic growth. We focus on net retention, ARR, and APV, with strong SaaS bookings. We expect continued growth due to investments and new product launches. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
29-07-2025
- Business
- Yahoo
Revvity Inc (RVTY) Q2 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ...
Revenue: $720 million in Q2, 3% organic growth. Adjusted EPS: $1.18, above expectations. Life Sciences Segment Growth: 4% organic growth. Diagnostics Segment Growth: 2% organic growth. Signals Software Growth: Over 30% organic growth. Free Cash Flow: $115 million in Q2, 83% conversion of adjusted net income. Operating Margin: 26.6% adjusted operating margin, down 210 basis points year over year. Share Repurchase: $293 million worth of shares repurchased in Q2. Full-Year Organic Growth Outlook: 2% to 4% range. Full-Year Adjusted EPS Outlook: $4.85 to $4.95. Net-Debt-to-Adjusted-EBITDA Ratio: 2.6 times. Adjusted Tax Rate: 19.1% in Q2. Warning! GuruFocus has detected 5 Warning Signs with RVTY. Release Date: July 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Revvity Inc (NYSE:RVTY) achieved 3% organic growth in Q2 2025, in line with expectations, driven by strong performance in the Life Sciences segment. The Signals Software franchise experienced approximately 30% growth, setting a new record for orders in a single quarter. Revvity Inc (NYSE:RVTY) reported adjusted EPS of $1.18, which was above expectations and guidance. The company generated $115 million in free cash flow during the quarter, maintaining a solid 90% conversion rate year-to-date. Revvity Inc (NYSE:RVTY) repurchased nearly $300 million worth of stock in Q2, bringing total repurchases to nearly $450 million for the first half of the year. Negative Points The Diagnostics segment faced challenges in China due to changes in hospital lab reimbursement policies, impacting the Immunodiagnostics business. Revvity Inc (NYSE:RVTY) lowered its full-year organic growth outlook to 2% to 4%, down 1% from prior expectations. The company anticipates a meaningful pullback in its Immunodiagnostics business in China for the remainder of the year. Operating margins were pressured by lower volumes of high-margin diagnostic tests and recent changes in FX rates. The academic and government customer segment continued to show weakness, with revenue declining in the low single digits year over year. Q & A Highlights Q: Can you explain the guidance change related to organic growth, particularly in China, and whether other factors like VBP are involved? A: (Prahlad Singh, CEO) The majority of the impact is from the DRG policy in China, which affects multiplex tests. This policy reduces test volumes, but in the long term, it may lead to more single-plex tests, which are more expensive. We are working with stakeholders to potentially reverse these changes due to their impact on patient care. Q: Regarding margin changes, what are your expectations for 2026 margins, and what growth assumptions are they based on? A: (Maxwell Krakowiak, CFO) We expect a baseline operating margin of 28% for 2026, with margin expansion depending on organic growth levels. Typically, with high single-digit growth, we expect a 75 basis point margin expansion, and with mid-single-digit growth, about 50 basis points. Q: What are the revenue pacing assumptions for this year, and how do you see the impact of NIH funding and year-end budget flush? A: (Maxwell Krakowiak, CFO) We expect normal seasonality with a high single-digit ramp in both Life Sciences and Diagnostics. The fourth quarter will see a ramp-up in gel and larger volume in Signals Software. We assume academic and government funding will remain weak for the rest of the year. Q: Can you provide insights into the Life Sciences segment's performance, particularly reagents and instruments, and any guidance changes? A: (Prahlad Singh, CEO) Pharma-biotech showed stability with mid-single-digit growth, and our Life Sciences reagents business has grown for five consecutive quarters. While capital equipment spending is impacted, we remain optimistic about the reagents business. Q: How is the Software segment performing, and what are the expectations for growth in the second half? A: (Prahlad Singh, CEO) The Signals Software business had a record quarter with 32% organic growth. We focus on net retention, ARR, and APV, with strong SaaS bookings. We expect continued growth due to investments and new product launches. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-07-2025
- Business
- Yahoo
Why Revvity (RVTY) Stock Is Falling Today
What Happened? Shares of life sciences company Revvity (NYSE:RVTY) fell 7.6% in the afternoon session after the company lowered its full-year profit forecast, which overshadowed its second-quarter earnings and revenue beat. Despite reporting second-quarter revenue of $720 million and an adjusted earnings per share (EPS) of $1.18, both of which surpassed analyst expectations, investors focused on the weaker outlook. Revvity trimmed its full-year adjusted EPS guidance to a range of $4.85 to $4.95. This revision was driven by multiple headwinds, including a double-digit decline in its diagnostics revenue from China, a key international market. The company also faced shrinking profitability, as both its adjusted operating and gross margins fell compared to the previous year. Management also pointed to potential costs related to tariffs. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Revvity? Access our full analysis report here, it's free. What Is The Market Telling Us Revvity's shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The previous big move we wrote about was 10 days ago when the stock dropped 3.2% as several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. Revvity is down 14.7% since the beginning of the year, and at $95.58 per share, it is trading 25.2% below its 52-week high of $127.75 from September 2024. Investors who bought $1,000 worth of Revvity's shares 5 years ago would now be looking at an investment worth $845.92. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-07-2025
- Business
- Yahoo
Revvity Slashes Outlook As China Policy Deals Diagnostics Blow
Revvity Inc. (NYSE:RVTY) stock is trading lower on Monday following the life science tools maker's second-quarter 2025 earnings report, which also included a trimmed profit forecast for 2025. The Massachusetts-based company announced second-quarter sales of $720.28 million, an increase from $691.69 million reported a year ago, surpassing the consensus estimate of $710.71 million. Delving into the financials, the company's adjusted earnings for the second quarter were $1.18, exceeding the consensus of $1.14. However, adjusted operating income decreased to $192 million from $199 million in the same period last year, and the adjusted operating profit margin also saw a decline to 26.6% compared to 28.8% a year company's life sciences segment saw revenue increase by 5% (+4% organically) to $366 million, led by approximately 30% growth in the Signals Software franchise. Diagnostics sales increased 3% year-over-year to $354 million, and organic diagnostics revenue increased 2%, in line with expectations, as immunodiagnostics franchise faced more difficult multiyear comparisons, limiting its growth to the low single digits this past quarter. Outlook Revvity lowered its fiscal year 2025 adjusted earnings from $4.90-$5.00 per share to $4.85-$4.95 per share compared to the consensus of $4.93. The company raised its 2025 sales guidance from $2.83 billion-$2.87 billion to $2.84 billion-$2.88 billion, versus the consensus of $2.85 billion. View more earnings on RVTY Revvity expects 2025 full-year organic growth to be in the 2% to 4% range, down 1% from the prior outlook, with reported growth of 3%- 5%. During the investor earnings call, Prahlad Singh, Revvity's CEO, president, and director, acknowledged the persistent macroeconomic and market challenges. 'The dynamic macro and market environment we experienced during the first quarter of the year continued through the second quarter and at this point, does not yet appear to be settling down as we enter the second half of the year,' Singh stated. A significant headwind identified by the company is a recent policy change in China concerning hospital laboratory reimbursement rules, specifically the implementation of Diagnosis-Related Groups (DRG). This expanded policy shift is impacting the size of diagnostic panels ordered by physicians in China, initially leading to a reduction in overall volumes for some of Revvity's multiplex products. While this may eventually drive an increase in demand for more expensive single-plex tests, which Revvity also offers, the immediate effect is a 'fairly meaningful pullback' in the company's immunodiagnostics business in China. Singh elaborated on the impact, noting that the immunodiagnostics business in China, which accounts for approximately 6% of Revvity's total revenue, is now projected to experience a high-teen percentage decline for the full year. This revised forecast for the critical China market is the primary driver behind Revvity's adjusted overall company outlook. Price Action: Revvity stock is trading lower by 9.98% to $93.32 at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Revvity Slashes Outlook As China Policy Deals Diagnostics Blow originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
